For example, in the case of BCR-ABL driven CML cells, ABL inhibition is therapeutically effective by reducing RTK activation rather than causing a significant reduction in ABL activity. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.